

16-27-05

JCO4 Filed PCT/PTO 26 OCT 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re:

Inventors: Banbury et al.

Atty. Docket No.: RPS6113-US

Serial No.: 10/534,117

Examiner: unassigned

Filing Date: May 5, 2005

Art Unit: unassigned

Corresponding PCT Application: PCT/US03/34934

Corresponding PCT Filing Date: 03 November 2003

Entitled: IMPROVED FORMULATIONS CONTAINING SUBSTITUTED IMIDAZOLE
DERIVATIVES

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.10(a)

Date of Deposit: 10/26/05

I hereby certify that this Information Disclosure Statement and PTO-1449 are being deposited with the U.S. Postal Service, as U.S. Express Mail No. EV 70635785048, postage prepaid, to: Commissioner for Patents, MAIL STOP - IDS (NO FEE), P.O. Box 1450, Alexandria, Virginia 22313-1450.

Jennifer Warner
Jennifer Warner

INFORMATION DISCLOSURE STATEMENT

As authorized and encouraged under 37 C.F.R. §§1.97-1.98 and the provisions of MPEP §§609 and 707.05(b), Applicants submit herewith certain patent references, publications and/or other information which the Patent and Trademark Office may wish to consider in examining the above-identified patent application. These references and information are listed below and on attached form PTO-1449.

U.S. PATENT DOCUMENTS

U.S. PATENT NUMBER	INVENTOR(S)
4,855,326	Fuisz
5,079,018	Ecanow
5,120,549	Gole et al.
5,298,261	Pebley et al.
5,948,430	Zerbe et al.
6,284,270	Lagoviyer et al.
6,316,026	Tartara et al.
6,375,982	Cherukuri
6,552,024	Chen et al.

FOREIGN PATENT DOCUMENTS

PATENT/DOCUMENT NUMBER	COUNTRY
WO 03/030881	PCT
WO 01/19336	PCT
WO 00/67694	PCT
WO 93/12769	PCT
WO 91/04757	PCT
EP0204045	EP
EP0618906	EP
EP0914818	EP
EP0974365	EP
GB1548022	UK

OTHER DOCUMENTS

1. Penttila et al., Effects of atipamezole – a selective α_2 -adreno-ceptor antagonist – on cardiac parasympathetic regulation in human subjects, *Autonomic & Autocoid Pharmacology*, 24, pp. 69-75, 2004

The identification of any document herein is not intended to be, and should not be understood as being an admission that each such document, in fact, constitutes "prior art" within the meaning of applicable law.

Copies of the non-US Patent Documents are enclosed herewith.


Applicants submit this statement in accordance with their duty of disclosure under 37 C.F.R. §1.56. This statement is filed in accordance with 37 C.F.R. §1.97(b)(3), before the mailing date of a first Office Action on the merits. Therefore, it is believed that as a result of no action being taken on this file as of the filing date of this disclosure, no fee is due by Applicant.

Applicant respectfully requests that the documents cited herein be made of record in the normal manner and that such documents appear on the printed patent as being considered and made of record.

Respectfully submitted,

Dated: Oct 25, 2005

By: Donald O. Nickey
Donald O. Nickey, Reg. No. 29,092
Attorney for Applicants
Cardinal Health, Inc.
7000 Cardinal Place
Dublin, Ohio 43017
Tel. (614) 757-5542
Fax (614) 757-2243



FORM PTO-1449 TO BE FILED WITH THE
INFORMATION DISCLOSURE STATEMENT

U.S. Department of Commerce
Patent and Trademark Office

Docket No.: RPS6113-US Serial No.: 10/534,117

Banbury et al.
Applicant

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

May 5, 2005
Filing Date

Not assigned
Group Art Unit

Not assigned
Examiner's Name

U.S. PATENT DOCUMENTS

Examiner's Initials	Document No.	Date	Inventor(s)	Class/Sub-class
	4,855,326	Aug. 8, 1989	Fuisz	514/777
	5,079,018	Jan. 7, 1992	Ecanow	426/385
	5,120,549	Jun. 9, 1992	Gole et al.	424/484*
	5,298,261	Mar. 29, 1994	Pebley et al.	424/488
	5,948,430	Sep. 7, 1999	Zerbe et al.	424/435
	6,284,270	Sep. 4, 2001	Lagoviyer et al.	424/464
	6,316,026	Nov. 13, 2001	Tatara et al.	424/464
	6,375,982	Apr. 23, 2002	Cherukuri	424/484
	6,552,024	Apr. 22, 2003	Chen et al.	514/252.16

*patent withdrawn according to USPTO database

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Document No.	Publication Date	Applicant(s)	Country
	WO 03/030881	17 Apr. 2003	Kosmos Pharma (US)	PCT
	WO 01/19336	22 Mar. 2001	CLL Pharma (FR)	PCT
	WO 00/67694	16 Nov. 2000	Electrosols Ltd. (GB)	PCT
	WO 93/12769	08 Jul. 1993	Yamanouchi Pharmaceutical Co., Ltd. (JP)	PCT
	WO 91/04757	18 Apr. 1991	Cima Labs, Inc. (US)	PCT
	EP 0204045	10 Dec, 1986	Bio/Data Corp. (US)	EP
	EP 0618906	22 Apr. 1998	Oy Juvantia Pharma Ltd. (FI)	EP
	EP0914818	08 Jun 2005	Kyowa Hakko Kogyo Co. (JP)	EP



FORM PTO-1449 TO BE FILED WITH THE
INFORMATION DISCLOSURE STATEMENT (cont'd)

U.S. Department of Commerce
Patent and Trademark Office

Docket No.: RPS6113-US Serial No.: 10/534,117

Examiner's Initials	Document No.	Publication Date	Applicant(s)	Country
	EP0974365	22 Sep. 2004	Permatec Technologie (CH)	EP
	GB1548022	04 Jul. 1979	Gregory et al.	GB (UK)

OTHER DOCUMENTS

1. Penttila et al., Effects of atipamezole – a selective $\alpha 2$ -adreno-ceptor antagonist – on cardiac parasympathetic regulation in human subjects, *Autonomic & Autocoid Pharmacology*, 24, pp. 69-75, 2004

Examiner: _____ Date Considered: _____

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant. The identification of any document herein is not intended to be, and should not be understood as being an admission that each such document, in fact, constitutes "prior art" within the meaning of applicable law since, for example, a given document may have a later effective date than at first seems apparent or the document may have an effective date which can be antedated. The "prior art" status of any document is a matter to be resolved during prosecution.